Today's Health Winners and Losers

Shares of Cambridge Antibody Technology (CATG Quote) were among the best-performing health-related stocks Monday, soaring 62% after AstraZeneca(AZN Quote) said it would buy the remaining part of Cambridge that it doesn't already own.

AstraZeneca, which already owned 19.2% of Cambridge, will pay $24.96 per American depository share for Cambridge, representing a 68% premium to Friday's closing price of $14.84. "This acquisition represents a major long-term strategic investment by AstraZeneca in novel biological therapeutics," AstraZeneca said in a press release. "It is our intention to both expand and broaden the scope of our discovery and development pipeline and we expect that, by 2010, up to a quarter of our candidates for full scale development will be biological therapeutic agents." Shares of Cambridge Antibody Technology recently were trading up $9.17 to $24.01, while shares of AstraZeneca fell 41 cents to $53.48.

Bioenvision(BIVN Quote) fell 4% after the company posted an in-line third-quarter loss. The biopharmaceutical company reported a loss of $8.2 million, or 20 cents a share, on revenue of $1.74 million. Excluding stock-based compensation costs, the loss was $6.2 million, or 15 cents a share. Analysts polled by Thomson First Call expected a loss of 15 cents a share, before items, on revenue of $1.18 million. During the year-earlier quarter, the company recorded an adjusted loss of $3.8 million, or 10 cents a share, on revenue of $1.4 million. Shares were trading down 25 cents to $5.70.

Shares of Langer(GAIT Quote) slumped 16% after the medical products company posted disappointing first-quarter results. The company posted a loss of $1.4 million, or 14 cents a share, on revenue of $8.3 million. One analyst had a forecast for a loss of 9 cents a share on revenue of $8.2 million. Last year, Langer reported a first-quarter profit of $1.4 million, or 22 cents a share, on revenue of $10.4 million. Those results included a one-time gain of $1.75 million. "Our results for the quarter ended March 31, 2006, reflect a loss of several customers at Silipos and the continued weakness in our custom foot orthotics business," the company said. Shares were trading down 77 cents to $3.98.